Specialty Chemicals and Ingredients M&A deal activity H1 2026

23 September 2026

Specialty Chemicals & Ingredients M&A: Specialised Capabilities Take Priority Over Scale

Specialty Chemicals & Ingredients M&A in H1 2026 confirmed the sector as one of Europe’s most active consolidation themes. With 98 transactions involving European players across industrial chemicals, feed & agriculture, food & beverage ingredients, and beauty & care ingredients, activity remained broad across the Specialty Chemicals & Ingredients M&A landscape. But the defining feature of the market was not simply deal volume: buyers increasingly prioritised application expertise, regulatory know-how, differentiated technologies, and specialised capabilities over manufacturing scale alone.

At MP Corporate Finance, we track M&A activity across the full Specialty Chemicals & Ingredients value chain. The first six months of 2026 highlighted three themes shaping the market: portfolio optimisation creating carve-out opportunities, quality assets continuing to command a premium, and acquisitions remaining an important route to innovation and differentiated technologies. At the same time, private equity activity remained significant and distressed opportunities became more frequent in energy-intensive segments.

Portfolio optimisation reshapes the Specialty Chemicals & Ingredients M&A landscape

Portfolio reshaping was one of the defining themes of H1 2026. Large corporates continued to reassess their portfolios and bring non-core divisions to market, creating opportunities for strategic buyers and private equity to acquire established platforms and specialised capabilities.

Several transactions illustrate this trend. CVC Advisers acquired an 80% stake in DSM’s Animal Nutrition business in a large-scale private equity carve-out focused on standalone value creation. Ambienta acquired McCormick’s flavour solutions business to establish an independent ingredients platform, while AEQUITA acquired SABIC’s European petrochemicals and advanced materials business. Distressed situations created additional opportunities. Domo Chemicals was acquired to secure local chemical and polymer production capacity, while Venator Germany’s pigment assets were acquired through an opportunistic consolidation. These transactions demonstrate how portfolio optimisation and more challenging conditions in energy-intensive businesses are creating different routes to consolidation.

Portfolio optimisation is creating opportunities across Specialty Chemicals & Ingredients, as corporate carve-outs, sponsor activity, and distressed situations bring strategically relevant assets to market.

Why quality assets command a premium in Specialty Chemicals M&A

Across all four end markets, premium assets are increasingly defined by specialised capabilities rather than production capacity alone. Application expertise, regulatory know-how, differentiated technologies, and defensible positions in attractive niches have become important elements of acquisition strategies.

In food & beverage ingredients, which led H1 activity with 35 deals, buyers focused on premium nutrition, natural flavours, and functional ingredients. Feed & agriculture recorded 25 deals, with investments spanning biological crop protection, animal and crop nutrition, and patented products. Industrial chemicals accounted for 22 deals, with buyers targeting resilient assets in chlor-alkali, polymers, and performance chemicals. The 16 beauty & care ingredients transactions centred on fragrance innovation, biotechnology, natural actives, and clinically supported ingredients.

The transactions themselves reinforce this pattern. Givaudan acquired Eurofragance to add niche perfumery capabilities, while BASF acquired AgBiTech to expand its biological crop protection portfolio. Agrifirm Group’s acquisition of Hamlet Protein strengthened its position in animal nutrition.

Quality still commands a premium: buyers are increasingly prioritising specialised capabilities, application expertise, regulatory know-how, and differentiated technologies over manufacturing scale.

Acquisitions as a route to innovation in Specialty Chemicals & Ingredients

Innovation continues to shape deal theses across the sector. Acquisitions and investments give buyers access to technologies, products, scientific expertise, and sustainability credentials that complement existing portfolios.

This is particularly visible in beauty & care ingredients. Chanel and several financial investors backed P2 Science, a sustainable cosmetic ingredients technology business, while Robertet acquired Aethera Biotech to add biotech-derived active ingredients to its natural cosmetics portfolio. In feed & agriculture, BASF’s acquisition of AgBiTech added biological crop protection capabilities alongside chemical solutions.

Food & beverage ingredients also saw transformational consolidation. Ingredion’s acquisition of Tate & Lyle was driven by scale and product synergies, while Nactarome continued its PE-backed buy-and-build strategy in natural flavours. Across these different transactions, M&A is being used to add capabilities and accelerate portfolio development.

Acquisitions remain a preferred route to foster lab-driven innovation, proprietary technologies, and sustainability credentials across Specialty Chemicals & Ingredients.

Valuation multiples in Specialty Chemicals & Ingredients M&A 2026

Public-market valuations indicate improving confidence across Specialty Chemicals & Ingredients. As of 30 June 2026, MP’s peer group traded at a median 10.7x LTM EV/EBITDA and 1.50x EV/Sales, with a median EBITDA margin of 15.0%. The headline median, however, masks considerable variation. LTM EV/EBITDA multiples ranged from 4.9x for Yara International to 24.5x for Covestro. Ingredients and beauty-focused businesses including Novozymes, Givaudan, Symrise, Sensient, and Croda traded considerably above the overall peer median.

The dispersion reflects the diversity of the sector and reinforces the importance of business mix, differentiation, profitability, and strategic positioning when assessing value.

Confidence is returning to valuations, but the wide dispersion in trading multiples reinforces the importance of quality and differentiation in determining value.

Specialty Chemicals & Ingredients M&A 2026: looking ahead

The first half of 2026 points to a market being shaped by building, reshaping, and differentiating. Corporate portfolio optimisation is bringing new assets to market, sponsors continue to participate across platforms and carve-outs, and strategic buyers are using acquisitions to access technologies and specialised capabilities.

The drivers differ across the four end markets, but the direction is consistent. Food & beverage ingredients buyers are pursuing premium and functional products; feed & agriculture is being shaped by science-backed innovation and regulatory expertise; industrial chemicals transactions favour differentiated process know-how and strategic manufacturing positions; and beauty & care ingredients continue to benefit from biotechnology, natural actives, and the convergence of beauty and wellness.

For owners active in Specialty Chemicals & Ingredients M&A, this places greater emphasis on differentiation, this places greater emphasis on differentiation. Businesses combining application expertise, regulatory know-how, proprietary technologies, or specialised capabilities with attractive end-market positions are aligned with the characteristics buyers prioritised throughout H1 2026.

In Specialty Chemicals & Ingredients M&A, scale alone is no longer enough. Specialised capabilities and differentiated technologies are increasingly defining strategic value.

If you would like to discuss what the current M&A environment means for your business, we would be happy to share our perspective. Get in touch with our expert!

Frequently Asked Questions

How active was the Specialty Chemicals & Ingredients M&A market in H1 2026?

The sector recorded 98 transactions involving European players in H1 2026. Food & beverage ingredients accounted for 35 deals, followed by feed & agriculture with 25, industrial chemicals with 22, and beauty & care ingredients with 16. Key investment themes range from premium nutrition and natural flavours to biological crop protection, differentiated process know-how, fragrances, biotechnology, and active ingredients.

What is driving Specialty Chemicals & Ingredients M&A in 2026?

Three themes stand out: portfolio optimisation, demand for specialised capabilities, and acquisitions as a route to innovation. Large corporates are divesting non-core businesses, sponsors remain active, and buyers increasingly prioritise application expertise, regulatory know-how, differentiated technologies, and proprietary products over manufacturing scale alone.

What are typical valuation multiples in Specialty Chemicals & Ingredients?

As of 30 June 2026, MP’s listed peer group traded at a median 10.7x LTM EV/EBITDA and 1.50x EV/Sales. Individual LTM EV/EBITDA multiples ranged from 4.9x to 24.5x, highlighting substantial differences between businesses based on their end-market exposure, profitability, differentiation, and strategic positioning.

How active are private equity investors in Specialty Chemicals & Ingredients M&A?

Private equity activity increased in H1 2026, with PE and PE-backed buyers involved in 37 transactions, up from 29 in H1 2025 — an increase of approximately 28%. PE and PE-backed buyers accounted for approximately 38% of the 98 transactions involving European players, putting financial investors nearly on par with private strategic buyers in terms of deal activity.